Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cynosure, Inc.
The private French firm’s new global head of R&D oncology spoke with Scrip about its two-pronged oncology strategy and its high hopes for the advanced glioma candidate, vorasidenib, which may improve upon Tibsovo.
Japanese bioventure Stella Pharma is re-designing a Phase II trial for its glioma candidate Steboronine after it was determined the original primary endpoint was not robust enough to prove efficacy, a challenge faced by some others working in the difficult indication. The drug was approved for head and neck cancer in Japan in 2020 and Stella has already announced a new collaboration which may be key to moving forward.
Prostate cancer patients press HHS for administrative hearing on march-in rights for patents covering Astellas’ Xtandi. While previous efforts have failed, petitioners believe they may have a shot this time around given Biden Administration and HHS Secretary Becerra’s views on the issue.
Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.
- Other Names / Subsidiaries
- Palomar Medical Techologies